Access and effectiveness of protease inhibitors in a field setting
Experience the future of the Tulane University Digital Library.
We invite you to visit the new Digital Collections website.
Description
The purpose of this study was to examine possible barriers to protease inhibitor therapy and to evaluate the effectiveness of protease inhibitor therapy in a field setting. A retrospective period cross-sectional study of HIV-infected individuals who received care from an HIV outpatient clinic between January 1996 and July 1998 was conducted. Logistic regression was used to determine socio-demographic and clinical characteristics associated with both receiving and responding to protease inhibitor therapy Of the 1874 individuals who were eligible for protease inhibitor therapy, 1004 (53.5%) had received protease inhibitor therapy. Individuals who received protease inhibitor therapy were more likely to be men (OR 1.38, [1.09--1.77]), less likely to be African-American (OR 1.86, [1.48--2.33]), less likely to have a history of substance use (OR 1.42, [1.15--1.76]), less likely to have a history of incarceration (OR 1.44, [1.00--2.07]), more likely to have attended the clinic within the past six months (OR 6.66, [4.98--8.92]), more likely to have a baseline CD4+ count below 200 cells/dl (OR 2.16, [1.74--2.70]), and more likely to have been diagnosed with an opportunistic process (OR 2.12, [1.68--2.69]) Of the 458 individuals who had received protease inhibitor therapy and had at least two viral load measurements, 200 (43.7%) experienced at least a one-log drop in viral load. Individuals who experienced at least a one-log drop in viral load were more likely to have a history of substance use (OR 1.65, [1.06--2-55]), more likely to have less than six months of antiretroviral therapy prior to initiating protease inhibitor therapy (OR 1.84, [1.16--2.92]), and less likely to have experience with more than one protease inhibitor (OR 2.02, [1.28--3.21]). In addition, in comparison to individuals who had a low baseline viral load, individuals who had a medium or high baseline viral load were more likely to experience a one-log drop in viral load (OR medium: 6.98, [4.14--11.79], OR high: 14.09, [7.49--26.50]) The results from this study indicate that there are barriers to receiving protease inhibitor therapy in a field setting. Additionally, this study demonstrates that not all individuals who receive protease inhibitor therapy experience at least a one-log drop in viral load